Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.

Abstract

Some patients with metastatic medulloblastoma can be successfully treated with targeted therapy. We report the case of a 42-year-old woman who was diagnosed with sonic hedgehog (SHH)-subgroup medulloblastoma. She was treated with surgery, radiation and chemotherapy. She then developed bone pain. A positron emission tomography (PET) scan confirmed widespread bone metastases from her medulloblastoma. She was started on vismodegib, an oral smoothened inhibitor that targets her tumour type. Her bone pain resolved. A repeat PET scan showed resolution of almost all metastases. Fourteen months after starting vismodegib, her disease recurred and she was transitioned to temozolomide chemotherapy. We document an important case of prolonged response to vismodegib in a patient with systemic SHH-subgroup medulloblastoma metastases.

• Authors: Seth A Climans, David R Macdonald, Duncan Ek Sutherland, Warren P Mason
• Journal: BMJ case reports (BMJ Case Rep) Vol. 13 Issue 10 (Oct 29 2020) ISSN: 1757-790X [Electronic] England
• PMID: 33122230 (Publication Type: Case Reports, Journal Article)
• Copyright: © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Anilides
• HhAntag691
• Pyridines

Topics

• Adult
• Anilides (therapeutic use)
• Cerebellar Neoplasms (diagnosis, drug therapy)
• Cerebellum (diagnostic imaging)
• Female
• Follow-Up Studies
• Humans
• Magnetic Resonance Imaging
• Medulloblastoma (diagnosis, drug therapy, secondary)
• Neoplasm Metastasis
• Positron Emission Tomography Computed Tomography
• Pyridines (therapeutic use)
• Time Factors
• Treatment Outcome